Peptide profiles.

The original FDA-approved GHRH analogue. Stimulates natural GH production through your own pituitary gland. Most natural approach to growth hormone optimization available.

The most clinically validated GHRH analogue available. FDA-approved for visceral fat reduction. Emerging data for cognitive protection in early Alzheimer's and MCI. Widely prescribed off-label for body composition and longevity.

The most selective GH secretagogue available. Stimulates strong growth hormone release with minimal cortisol or prolactin side effects. Considered the gold standard secretagogue.

Mitochondria-derived peptide discovered in 2015. Acts as an exercise mimetic by activating the same metabolic pathways triggered by physical activity. Levels naturally decline with age.

A triple-action metabolic research compound combining GLP-1, GLP-2, and GLP-3 receptor activity. Studied for metabolic regulation, gut health, and appetite modulation in preclinical models.

The most commonly prescribed GH secretagogue combination in US longevity medicine. CJC-1295 provides GHRH stimulation while Ipamorelin provides ghrelin receptor stimulation — two complementary pathways for natural GH optimization.

A proprietary AminoClub peptide blend formulated for metabolic optimization, body composition, and longevity. Targets the GH axis, metabolic pathways, and cellular health simultaneously.

The most selective growth hormone secretagogue available. Stimulates strong GH release with minimal cortisol or prolactin side effects. Gold standard for GH axis optimization.

Potent GH secretagogue with stronger GH pulse than Ipamorelin but significant cortisol and prolactin elevation. Largely replaced by Ipamorelin in clinical settings.

Early GH secretagogue notable for strong appetite stimulation via ghrelin pathway. Studied for cachexia and muscle wasting. Also has gastroprotective properties similar to BPC-157.

Fat-burning fragment of human growth hormone. Stimulates lipolysis without the anabolic or glucose effects of full GH. Completed Phase IIb human trials. Program paused vs GLP-1 competition.

A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly. Phase 2 data showed up to 24.2% body-weight reduction at 12mg over 48 weeks — exceeding semaglutide and tirzepatide in early comparisons. Phase 3 TRIUMPH trials ongoing. Most legally sensitive GLP-1 adjacent compound in the current market — Eli Lilly has actively pursued legal action against vendors selling it as RUO.

FDA-approved dual GLP-1/GIP receptor agonist. Approved as Mounjaro for type 2 diabetes (2022) and Zepbound for obesity (2023). SURMOUNT trials showed approximately 21% average body-weight reduction at 15mg — outperforming semaglutide in head-to-head data. Developed by Eli Lilly. Compounding pathway effectively closed — Eli Lilly has aggressively pursued legal action against pharmacies compounding tirzepatide.

A small molecule NNMT (Nicotinamide N-methyltransferase) inhibitor — not technically a peptide, but a research compound widely carried by peptide vendors with significant interest in longevity and metabolic research communities. NNMT is an enzyme that consumes NAD+ precursors and promotes fat storage. Inhibiting it raises NAD+ levels and shifts metabolism toward fat burning. Animal data is promising. Human research is limited.

The body's master antioxidant — a tripeptide naturally produced in every cell, responsible for neutralizing free radicals, supporting detoxification, and regulating immune function. Levels decline with age and under chronic stress. Among the most researched compounds in this database with genuine human clinical trial data across multiple conditions. IV glutathione is widely used in longevity and integrative medicine clinics.